Several rhythmic components were previously mapped for salivary and/or urinary CA125 and CA130. On the back-ground of such reference standards, OVX1 and M-CSF were assayed on 242 urine samples and 160 saliva samples provided by a 71-year-old patient with a Mullerian/ovarian adenocarcinoma. Serum OVX1 correlates with serum CA125 (P=0.002) when circulating CA125 concentrations decreased (from 122 to 14 U/ml), the urinary excretion rate of OVX1 decreased (P=0.005), whereas the urinary excretion rate of CA125 increased (P<0.001). Salivary OVX1 and urinary M-CSF show ultradian variations (with a frequency of one cycle in 14-17 hours), which could be utilized to guide treatment timing targetted first to optimize treatment efficacy and as a second consideration to minimize treatment toxicity.
|Original language||English (US)|
|Number of pages||6|
|State||Published - Jan 1 1995|
- Ovarian cancer
- Urine treatment timing